A Compassionate Use Program of Idarucizumab for Reversal of the Anticoagulant Effects of Dabigatran in Japanese Patients Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures

Trial Profile

A Compassionate Use Program of Idarucizumab for Reversal of the Anticoagulant Effects of Dabigatran in Japanese Patients Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Idarucizumab (Primary)
  • Indications Blood coagulation disorders; Haemorrhage
  • Focus Adverse reactions; Expanded access
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 08 Feb 2017 Status changed from recruiting to completed.
    • 19 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top